DRUG THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: TARGET PATIENT GROUPS AND DRUG THERAPY POSSIBILITIES
https://doi.org/10.17802/2306-1278-2019-8-1-80-89
Abstract
The review article updates current data concerning drug therapy in patients with acute coronary syndrome (ACS) of different types. High refusal rate to invasive management among patients with ACS in our country suggests that the need for optimizing drug therapy. Recent epidemiological data are presented in addition to the main target groups of patients who do not receive invasive treatment: elderly patients, patients with multivessel coronary artery disease and distal lesions and those who have chronic kidney disease. The general patient profile who will be prescribed drug therapy is presented. The optimal drug therapy regimens for patients with different ACS types are provided.
About the Authors
I. N. Suspitsyna
Regional State Budgetary Healthcare Institution “Altai Regional Cardiology Dispensary”;
Altai State Medical University
Russian Federation
Russian Federation
PhD, cardiologist at the Cardiology Department for Patients with Acute Myocardial Infarction, 46, Malakhov St., Barnaul, 656055;
assistant lecturer at the Department of Anaesthesiology, Intensive Care and Clinical Pharmacology, 40, Lenina St, Barnaul, 656038
I. A. Sukmanova
Regional State Budgetary Healthcare Institution “Altai Regional Cardiology Dispensary”;
Altai State Medical University
Russian Federation
Russian Federation
PhD, Head of the Cardiology Department for Patients with Acute Myocardial Infarction, 46, Malakhov St., Barnaul, 656055;
Associate Professor at the Department of Therapy and General Practice, 40, Lenina St, Barnaul, 656038
References
1. Jia H., Dai J., Hou J., Xing L., Ma L., Liu H., Xu M., Yao Y., Hu S., Yamamoto E., Lee H., Zhang S., Yu B., Jang I.K. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017 Mar 14;38(11):792-800. doi: 10.1093/eurheartj/ehw381.
2. Menozzi A., De Luca L., Olivari Z., Rossini R., Ferlini M., Lina D. Patients with non-ST-elevation acute coronary syndrome managed without coronary revascularization: an undertreated population. G Ital Cardiol (Rome). 2016 Oct;17(10):816-826. doi: 10.1714/2464.25800.
3. Orenes-Piñero E., Ruiz-Nodar J.M., Esteve-Pastor M.A., Quintana-Giner M., Rivera-Caravaca J.M., Veliz A. Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. Oncotarget. 2017 Sep 24;8(46):80182-80191. doi: 10.18632/oncotarget.21260.
4. A.D. Erlikh, N.A. Gratsiansky on behalf of RECORD-3 participants Registry of Acute Coronary Syndromes «RECORD-3». Characteristics of Patients and Treatment During Initial Hospitalization. Kardiologiia. 2016. 56 (4):. 16-24. (In Russian) DOI: https://dx.doi.org/10.18565/cardio.2016.4.16-24
5. Steg P.G., James S.K., Atar D., Badano L.P., BlömstromLundqvist C., Borger M.A. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segmention elevation: Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.
6. Roffi M., Patrono C., Collet J. P., Mueller .C, Valgimigli M., Andreotti F. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Forse for the Managemeht of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320
7. 1. Gleser M.G., Astashkin E.I., Kiseleva A.E. Is it Possible to Improve Results in the Conservative Treatment Strategy in Patients With Acute Coronary Syndrome? Kardiologiia. 2016; 56 (9): 69-74. (In Russian) DOI: http://dx.doi.org/10.18565/cardio.2016.9.69-74
8. Ying-Qing L.,L. L.Na, L. Jian-Hua Outcomes in patients with non-ST-elevation acute coronary syndrome randomly assigned to invasive versus conservative treatment strategies: A meta-analysis.Clinics (Sao Paulo). 2014 Jun;69(6):398-404
9. Giannitsis E., Wallentin L., James S.K., Bertilsson M., Siegbahn A., Storey R.F. Outcomes after planned invasive or conservative treatment strategy in patients with non-STelevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. Eur Heart J Acute Cardiovasc Care. 2017; 6(6) : 500-510. doi: 10.1177/2048872616641901.
10. Wallentin L., Lindhagen L., Ärnström E., Husted S., Janzon M., Johnsen S.P. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016 Oct 15;388(10054):1903-1911. doi: 10.1016/S0140-6736(16)31276-4
11. Elgendy I.Y., Mahmoud A.N., Mansoor H., Bavry A.A. Early Invasive Versus Initial Conservative Strategies for Women with None ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis. Am J Med. 2017 Sep;130(9):1059-1067. doi: 10.1016/j.amjmed.2017.01.049.
12. Amann U., Kirchberger I., Heier M. Thilo C., Kuch B., Peters A., Meisinger C. Predictors of non-invasive therapy and 28-day-case fatality in elderly compared to younger patients with acute myocardial infarction: an observational study from the MONICA/KORA Myocardial Infarction Registry. BMC Cardiovasc Disord. 2016 Jul 13;16:151. doi: 10.1186/s12872-016-0322-3.
13. Janzon M., James S., Cannon C.P., Storey R.F., Mellström C., Nicolau J.C., Wallentin L., Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan;101(2):119-25. doi: 10.1136/heartjnl-2014-305864.
14. Kashtalap V.V., Barbarash O.L. Patient with acute acute coronary syndrome withtion ST-segment elevation and conservative management. Pharmacological options to improve prognosis. Medicinsij sovet. 2017: 7: 28-38 (In Russian) DOI: 10.21518/2079-701X-2017-7-28-38
15. Erlikh A.D. Twelve mounths outcome in patients wish acute coronary syndrome, by the national registry «RECORD-3». Russian Journal of Cardiology. 2018;(3):23-30. (In Russian) https://doi.org/10.15829/1560-4071-2018-3-23-30
16. Olivari Z., Steffenino G., Savonitto S., Chiarella F., Chinaglia A., Lucci D. et al. The management of acute myocardial infarction in the cardiological intensive care units in Italy: the ‘BLITZ 4 Qualitа’ campaign for performance measurement and quality improvement. Eur Heart J Acute Cardiovasc Care 2012;1:143-52. doi: 10.1177/2048872612450520.
17. Marcovic D., Radanovic A., Milovilovic A., Bozic J., Lukin A., Simunic M. Effects of a percutaneous coronary intervention or conservative treatment strategy on treatment outcomes in elderly female patients with acute coronary syndrome. Signa Vitae. 2016; 12(1): 96-100 (19)10.22514/SV121.102016.16
18. Poon S., Goodman S.G., Yan R.T., Bugiardini R., Bierman A.S., Eagle K.A. et al. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J 2012 Jan; 163(1): 66–73. doi: 10.1016/j.ahj.2011.09.025.
19. Padilla I.М., Martín-Asenjo R., Bueno H. Management of Acute Coronary Syndromes in Geriatric Patients. Heart Lung Circ. 2017 Feb;26(2):107-113. doi: 10.1016/j.hlc.2016.07.008
20. Engberding, N., Wenger N. K. Acute Coronary Syndromes in the Elderly. F1000Res. 2017 Oct 2;6:1791. doi: 10.12688/f1000research.11064.1.
21. Leonardi S., Bueno H., Ahrens I., Hassager C., Bonnefoy E., Lettino M. Optimised care of elderly patients with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care. 2018; 7 (3): 287-295 doi: 10.1177/2048872618761621
22. Carroll K.A., Early N.K., Tsu L.V. Managing acute coronary syndromes in the elderly. Consult Pharm. 2015; 30:265- 282. doi: 10.4140/TCP.n.2015.265.
23. Capodanno D., Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010; 56:1683-1692. doi: 10.1016/j.jacc.2010.04.063.
24. Zaman M.J., Stirling S., Shepstone .L, Ryding A., Flather M., Bachmann M., Myint P.K. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J. 2014; 35:1551-1558. DOI: https://doi.org/10.1093/eurheartj/ehu039
25. Bugiardini R., Eskola M., Huhtala H., Niemelä K., Karhunen P., Miglio R., Manfrini O., Pizzi C., Nikus K. Coronary revascularisation in stable patients after an acute coronary syndrome: a propensity analysis of early invasive versus conservative management in a register-based cohort study. BMJ Open. 2013;3:e002559. doi:10.1136/bmjopen-2013-002559
26. Cannon C.P., Harrington R.A., James S., Ardissino D., Becker R.C., Emanuelsson H. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized doubleblind study. Lancet. 2010; 375:283- 293. DOI:10.1016/S0140-6736(09)62191-7
27. Levine G., Bates E.R., Bittl J.A., Brindis R.G., Fihn S.D., Fleisher L.A. et al. 2016 ACC/AHA guideline focused update on duration of antiplatelet therapy in patient with coronary heart disease. A Report or the American College of Cardiology /American Heart Association Task Force on Clinical Practice Guidelints. Circulation. 2016 Sep 6;134(10):e123-55. doi: 10.1161/CIR.0000000000000404.
28. Costa F., van Klaveren D., James S., Heg D., Räber L., Feres F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389: 1025–1034. doi: 10.1016/S0140- 6736(17)30397-5.
29. Yeh R.W., Secemsky E.A., Kereiakes D.J., Normand S.L., Gershlick A.H., Cohen D.J. et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016; 315: 1735–1749. doi:10.1001/jama.2016.3775
30. Montalescot G., Bolognese L., Dudek D., Goldstein P., Hamm C., Tanguay J.F. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369:999–1010. doi: 10.1056/NEJMoa1308075.
31. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2018; 40 (3): 237- 269. doi:10.1093/eurheartj/ehy462
32. Ryabov V.V., Syrkina A.G., Belokopytova N.V., Markov V.A., Erlikh A.D. ST elevation acute coronary syndrome in nonobstructive lesion of coronary arteries: data from the registry «RECORD-3». Russian Journal of Cardiology. 2017;(11):15-21. (In Russ.) https://doi.org/10.15829/1560-4071-2017-11-15-21
33. De Ferrari G.M., Fox K.A., White J.A., Giugliano R.P., Tricoci P., Reynolds H.R. et al. Outcomes among nonST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014;3:37–45. doi: 10.1177/2048872613489315. Epub 2013 May 9.
34. Bueno H, Sinnaeve P., Annemans L., Danchin N., Licour M., Medina J. et al.; EPICOR Investigators. Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: insights from EPICOR, an international study of current practice patterns. Eur Heart J Acute Cardiovasc Care 2016;5:3-12. doi: 10.1177/2048872614565912.
35. Bhatia S., Arora S., Bhatia S.M., Al-Hijji M., Reddy Y.N.V., Patel P., Rihal C.S., Gersh B.J., Deshmukh A. Non– ST-Segment–Elevation Myocardial Infarction Among Patients With Chronic Kidney Disease: A Propensity Score–Matched Comparison of Percutaneous Coronary Intervention Versus Conservative Management. J Am Heart Assoc. 2018 Mar 10;7(6). pii: e007920. doi: 10.1161/JAHA.117.007920.
36. Aldrovandi A., Cademartiri F., Arduini D., Lina D., Ugo .F, Maffei E. et al. Computed tomography coronary angiography in patients with acute myocardial infarction without significant coronary stenosis. Circulation 2012; 126:3000-7. doi: 10.1161/CIRCULATIONAHA.112.117598.
37. Yavelov I.S. Prolonged Dual Antiplatelet Therapy after Myocardial Infarction: what the Results of the PEGASUSTIMI 54 Trial Show. Rational Pharmacotherapy in Cardiology 2017;13(4):558-564. (In Russ). DOI: 10.20996/1819-6446-2017-13-4-558-564
38. Ruda M.Y., Syrkin A.I., Panchenko E.P., Yavelov I.S., Averkov O.V., Shahnovich R.M., Komarov A.L. Summary of conclusions from a consensus panel of experts on the importance of rivaroxaban in the management of patients recovering from acute coronary syndrome. Atherothrombosis Journal. 2015;(2):86-94. (In Russ.) https://doi.org/10.21518/2307-1109-2015-2-86-94
Review
For citations:
Suspitsyna I.N., Sukmanova I.A. DRUG THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: TARGET PATIENT GROUPS AND DRUG THERAPY POSSIBILITIES. Complex Issues of Cardiovascular Diseases. 2019;8(1):80-89. (In Russ.) https://doi.org/10.17802/2306-1278-2019-8-1-80-89
Views:
999
